A 60-year-old man with alcoholic cirrhosis underwent regadenoson SPECT myocardial perfusion imaging as a part of liver transplant evaluation. His current medications included spironolactone 50 mg daily, furosemide, and nadolol. The rest and stress ECGs and the perfusion images were normal (Figure 1A). The left ventricular ejection fraction was 70%. The raw images showed tracer uptake in both breasts and both breasts appeared large ( Figure 1B ).
CASE PRESENTATION
A 60-year-old man with alcoholic cirrhosis underwent regadenoson SPECT myocardial perfusion imaging as a part of liver transplant evaluation. His current medications included spironolactone 50 mg daily, furosemide, and nadolol. The rest and stress ECGs and the perfusion images were normal (Figure 1A) . The left ventricular ejection fraction was 70%. The raw images showed tracer uptake in both breasts and both breasts appeared large ( Figure 1B ).
Comments
We attribute the gynecomastia in this man to spironolactone. Although liver cirrhosis can cause gynecomastia, it usually does not result in increased tracer uptake in the breast tissue. This is the first such case in our experience in hundreds of patients studied before liver transplantation. 1 The gynecomastia can be painful and may be reversible once spironolactone is discontinued. A medication history may prevent unnecessary testing to elucidate the etiology. Discontinuation of spironolactone, and substitution with eplerenone if indicated, is recommended. 
